Joint radionuclide therapy and immunotherapy approach. The combination shows promising therapeutic option for prostate cancer patients.
Read full article >>
Other news & events
- News01.07.2026

Türkiye Introduces Reimbursement for Actinium-225 PSMA Therapy
Read more - News12.05.2026

#ASCO26 - Radiopharmaceutical Therapy in Oncology: Practical Integration for Practicing Oncologists
Read more - News11.05.2026

Oncidium foundation partners with Curium to expand access to Radioligand Therapy worldwide
Read more




